JT3 (@Joshthe3rd_) header
JT3 (@Joshthe3rd_) profile picture

Always learning from mistakes and always adapting. https://nitter.gq/t.co/ddEatJXh6c (Charts + Notes posted here as well)

Antarctica
Joined February 2021
*Updated* 500M+ Biotech Public Offerings 2024-2026 (6/20/26) added (CYTK) I will create a new one at YE. $XBI
1/ 500M+ biotech offerings 2024-2026 $XBI ABVX - 743M PO at 64.00 (2025) INSM - 750M PO at 96.00 (2025) PCVX - 1.3B PO at 103.00 (2024) PCVX - 632M PO at 50.00 (51.00) VKTX - 550M PO at 85.00 (2024) IONS - 500M PO at 43.50 (2024) RVMD - 750M PO at 46.00 (2024) RVMD - 1.65B PO
3
5
2
43
37,445
$KYNB "Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027." This is a fancy way of saying they will be seeking strategic alternatives in Q1 2027.
2
473
$PASG will be worth revisiting after the merger. sec.gov/Archives/edgar/data/…
385
Due to all the planes being grounded all biotech M&A is paused for now. Sorry guys.
The @FAAnews issued a nationwide ground stop for all U.S. airports following a communication issue impacting all Air Route Traffic Control Centers. FAA technicians are investigating the issue. We will provide immediate updates as we have them.
1
1
19
1,261
This is going to be close
8
362
$MTRI should continue to bounce/rally off the 200MA daily.
1
1
403
probably will become the next SYRE style runner over the next few years
184
We are always only 2 affairs away from crashing the stock market.
2
307
JT3 retweeted
Biotech CEOs are usually so poor that they can only have regulatory Affairs.
22
62
7
723
34,017
$LGVN cash is low. Just need them to update their "cash conservation measures" and seee some signs of bottoming then they are good to go for strat alt. As long as they don't dilute the piss out of it to keep the low float it could spike like NXTC did on a merger announcement.
2
4
932
Interesting trend 🤔 Especially when you time stamp these and know the float at the time. Would prefer some better TA signs of bottoming though.
136
$CNSP would prefer to snag shares at the private placement price at 2.30. Volume is non-existent though.
303
$TCRX cash through end of 2027. Preclin data for in-vivo tumor asset in q1 2027. If they can't raise then will be forced to strat alt. We wait for now.
296
$XBI despite the carnage still maintaining a decent trend on the daily. Should retest the 200MA daily though.
1
2
421
Days of the old XBI are behind us. Now the index has higher quality commercial/p2/3 names flush with cash. We will have dips, but willing to bet they will be less exaggerated then the ones in the past. Though high risk clinical biotechs 100% got nuked and look like the old XBI.
205